Business
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
SHANGHAI & CAMBRIDGE, Mass., May 11, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company’s potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs) following progression after standard first-line therapy. epNECs are an aggressive maligna
About this update from Zai Lab Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/3351223da5217016bf46a46ce1614fb5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ljaLRomm6tMkR2MzziXUvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0OA--/https://media.zenfs.com/en/business-wire.com/3351223da5217016bf46a46ce1614fb5","width":480,"height":224},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/d_1.6xK_KJo9U0d4m37g1A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI5OQ--/https://media.zenfs.com/en/business-wire.com/3351223da5217016bf46a46ce1614fb5","width":480,"height":224}},"lazy":false},{"type":"text","content":"- epNECs are aggressive malignancies with poor prognosis and no approved therapies, representing significant unmet medical need- Preliminary clinical data recently presented at the AACR Annual Meeting suggest zoci has potential to be a first-in-class therapy for epNECs- Zoci NEC clinical program is advancing toward registration, with active engagement with Health Authorities underway","length":388,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI & CAMBRIDGE, Mass., May 11, 2026--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company’s potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs) following progression after standard first-line therapy. epNECs are an aggressive malignancy affecting approximately 100,000 people worldwide, with no targeted therapies and no approved standard of care in previously treated disease.","length":665,"tagName":"p"},{"type":"text","content":""This is the second FDA Fast Track Designation for zoci, underscoring the significant potential of this investigational medication to provide an important new treatment option for patients with difficult-to-treat cancers that have few available therapies," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "This designation will support our efforts to advance this novel therapy through clinical development with b...